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ABSTRACT: 
This chapter analyses major issues surrounding the Annual Report Questionnaire (ARQ) – the key 
mechanism through which the UN collects data on various facets of the world’s illicit drug market. 
As the ARQ is currently under review by the United Nations Office on Drugs and Crime (UNODC), the 
authors suggest ways to incorporate the gains made at the United Nations General Assembly Special 
Session on the World Drug Problem (UNGASS).  
 
The UNGASS Outcome Document has, to certain degree, enabled the international community to 
move away from the simplistic goals of a drug-free world enshrined in the 2009 Political Declaration 
and towards a more comprehensive health- and human rights-based approach. The UNGASS has 
also laid important groundwork for the 2019 Ministerial Segment, where member states will 
delineate the global drug control approach for the next decade. In this context, the issue of metrics 
and indicators has a critical political role to play as it will shape how member states will measure 
progress against their international drug control commitments.  
 
Starting with a review of the ‘triple trouble’ – poor data quality, low response rates from Member 
States and other inconsistencies that have long persisted with the ARQ – the chapter moves on to 
offer substantive critiques on the content of the Questionnaire and ways to better incorporate 
issues related to health, human rights and development. The chapter concludes by providing 
guidance on possible synergies with the Outcome Document and the Sustainable Development 
Goals, bringing international drug control in line with the UN Charter.  
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Measuring the ‘world drug problem’: 2019 and beyond 
David R. Bewley-Taylor and Marie Nougier 
Introduction  
Almost two years after the United Nations General Assembly Special Session on the World Drug 
Problem (UNGASS), the implications of the resultant Outcome Document (UN, 2016) remain unclear, 
and complex. At a structural level, it can legitimately be regarded as a homeostatic text that does 
much to help prop up the increasingly creaky UN international drug control framework (Bewley-
Taylor, D., & Jelsma, M. ,2016). Yet, as member states move to operationalize its key provisions, it is 
becoming increasingly obvious that the Document has in fact generated considerable concern among 
what might be called ‘status quo countries’ seeking to preserve the treaty system in its current form. 
One need only look at the debates and country statements within the UN’s central policy making body 
on the drugs issue, the Vienna based Commission on Narcotic Drugs (CND or Commission) for evidence 
to support this view (IDPC, 2017). That prohibition-oriented states like the Russian Federation are 
investing considerable effort and political capital to argue that the Outcome Document does not 
supplant previous soft law instruments, particularly the 2009 Political Declaration and Plan of Action 
(UN, 2009), suggests that the progressive character of the Document exceeds what might have been 
initially thought as the dust settled in April 2016.  Although problematic in many respects, the 2016 
instrument does to a certain degree move away from the 2009 Political Declaration’s simplistic goal 
for states to ‘eliminate or reduce significantly and measurably’ illicit drug supply and demand, the 
diversion and trafficking of precursors and money laundering. This, is should be recalled, was agreed 
nearly ten years ago with a target date of 2019.   While the operationalization of many aspects of the 
Outcome Document merit ongoing scrutiny, key among them is how the international community 
refines its measurement of what has become known simply and somewhat vaguely as the ‘world drug 
problem’.  This is especially so as we approach what has now been agreed to be a high-level ministerial 
segment of the CND in March 2019 (UNODC, 2017) and not only what is likely to be an awkward review 
of progress made against the targets within the Political Declaration, but also negotiations regarding 
how the Commission approaches international drug control in the next decade. Beginning with an 
overview of the Annual Report Questionnaire (ARQ), the key mechanism by which the UN system 
collects data on various facets of the state of the world’s illicit drug market, this chapter examines the 
content of the UNGASS Outcome Document in terms of its reference to indicators and some of the 
problems surrounding the current framework. It then goes on to discuss the increasing attention given 
to the ARQ within Vienna since the UNGASS before concluding with a critique of the process leading 
to the meeting of an ‘Expert Group’ to revise the ARQ; a Group scheduled to meet for the first time in 
January 2018 (UNODC, 2018).    
The Annual Report Questionnaire: Triple trouble.   
The ARQ has long been core to the UN drug control system’s attempts to monitor and better 
understand the state of the ‘world drug problem’. The not unreasonable logic here is that the resultant 
knowledge will assist national authorities in the design and implementation of effective drug control 
policies in line with obligations and goals under the international drug control conventions and 
complementary soft law instruments, including CND resolutions and high-level documents like that 
emanating from the UNGASS. While non-binding for states, such instruments possess considerable 
normative power and influence. In terms of hard law, the conventions formally oblige States Parties 
to provide data each year concerning the situation in their countries to the Secretary General (UNODC, 
1961) – in practice the Secretariat of the UN Office on Drugs and Crime (UNODC or Office), the body 
mandated to assist Member States ‘in their struggle against illicit drugs, crime and terrorism (UNODC, 
1971).  This mechanism dates to the pre-UN foundational era of the international drug control system, 
including the requirement to submit annual reports from States parties contained within the 1931 
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Convention for Limiting the Manufacture and Regulating the Distribution of Narcotic Drugs. At various 
points since 1945, and the transfer of the international control machinery to the UN, the reporting 
system was reviewed and revised (ECOSOC, 1994; UNODC, 2000). Notably, in December 1999 the CND 
‘adopted a unified single questionnaire that included information required on all action plans and 
measures adopted by the General Assembly at its twentieth Special Session’, that is to say the 1998 
UNGASS on the ‘world drug problem’ (UN, 2001). More recently, in 2010, the CND endorsed a revised 
version of the questionnaire ‘to enable the monitoring of and biennial reporting to the Commission 
on the implementation by Member States of the Political Declaration and Plan of Action on 
International Cooperation towards an Integrated and Balanced Strategy to Counter the World Drug 
Problem, as well as for the reporting to the Commission mandated by the three international drug 
control conventions (UNODC, 2010).’ The review processes usually involve some form of expert group, 
for example the ‘open-ended expert group on data collection’ mandated by Resolution 53/16 in 2010 
(UNODC, 2010). Of note is the fact that, among other things, this resolution stresses that the ARQ 
‘should be periodically reviewed in order to have a flexible instrument allowing the reporting of 
national and emerging drug situations (UN, 2010).’  
Having been revised and streamlined at various points over the years, the ARQ is currently structured 
in the following way:  
- Part I: Legislative and institutional framework 
- Part II: Comprehensive approach to drug demand reduction and supply 
- Part III: Extent and patterns of drug use 
- Part IV: Extent and patterns of and trends in drug crop cultivation and drug manufacture and 
trafficking.   
With UNODC acknowledging that sometimes there is insufficient data to provide an ‘accurate or 
comprehensive picture of world drug markets,’ the Questionnaire is supplemented by a range of other 
sources. In addition to official national publications, these include the Heads of National Law 
Enforcement Agencies (HONLEA), the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA), the Inter-American Drug Abuse Control Commission (CICAD) and the Drug Abuse 
Information Network for Asia and the Pacific (DAINAP) (UNODC, 2017). 
As UNODC itself notes, there remain considerable problems with the reporting system, particularly 
regarding the quality of responses from member states.  For example, in relation to the ARQ for 2015, 
the key source of data upon which the UNODC’s World Drug Report 2017 is based, out of 199 potential 
respondents (including 193 Member States), the Office received only 98 replies to its questionnaire 
on Part III (down from 101 the previous year) and 101 replies to Part IV (down from 104 the previous 
year). ‘The best coverage’, UNODC notes, ‘was from Europe (where 80 per cent of the respondents 
provided a reply), Asia (63 per cent) and the Americas (57 per cent). Reflecting one of the major 
challenges in data collection, in the case of Africa, however, ‘only 24 per cent of the Member States 
replied’. And in the Oceania region, only two out of the 16 countries, responded to the ARQ.   
In addition to the response rates themselves, there is significant variation in the quality of data 
provided. Again, as UNODC recognises in relation to the 2015 Questionnaire, ‘the quantity of data 
provided on illicit drug supply is “significantly better” than that provided on drug demand.’ More 
specifically, ‘79 per cent of ARQs part iv were “substantially completed”, compared to 67 per cent of 
ARQs part iii.’ ‘It should be noted,’ the Office goes on to say, ‘that those ARQs that were more than 50 
per cent completed were classed as having been “substantially filled in”, while those having less than 
50 per cent completion were classed as “partially filled in” (UNODC, 2017). Mindful of the complexities 
and financial cost of data capture, response rates and the quality and completeness of information 
returned within the Questionnaire is often dependent on frameworks and mechanisms within 
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member states. As understandable as this may be for many countries, variable quality data impact the 
accuracy of the picture generated, with irregular returns having the potential to influence reported 
trends ‘in a given year’ (UNODC, 2017). Indeed, although the World Drug Report 2017 states that the 
‘drug market is thriving’ (UNODC, 2017), as has been discussed at length elsewhere, data gaps and 
incomplete and poor-quality data sets generate high levels of uncertainty concerning the true state of 
the ‘world drug problem’. This includes a likely underestimation of the scale and complexity of drugs 
markets in some regions, especially Africa and Asia (IDPC, 2016).  
Reducing the levels of uncertainty through an improvement in the quality of the existing data sets 
clearly remains an ongoing issue of concern; and one that is certainly not new. Writing about data 
collection in their seminal 1975 book, The Gentlemen’s Club: International Control of Drugs and 
Alcohol, Kettil Bruun, Lynn Pan and Ingemar Rexed point out ‘the paucity of information in the national 
reports to the UN’ in the early 1970s (Bruun, K., Pan, L., and Rexed, I., 1975). Regarding data ‘given to 
the secretariats’ of the Commission and the Division on Narcotic Drugs (a predecessor body of the 
Office) ‘by governments under their treaty obligations’, the authors note that this ‘information is quite 
inadequate’ and that the ‘questionnaires used for such reporting are in need of overhauling’. 
Interestingly, a key topic of concern raised by research at that point related to ‘returns under the 
heading “drug abuse.”’ Here Bruun, Pan and Rexed note how a ‘systematic study of these reveals the 
limited value of the information given’ (emphasis added) (Bruun, K., Pan, L., and Rexed, I., 1975). 
Today, while not focusing specifically on drug use, such a perspective is finding increasing resonance. 
Indeed, while there is a widely held view that gaps in the data pose considerable analytical dilemmas, 
questions are also being increasingly asked concerning the type and worth of the data that is being 
collected. Adding another problematizing layer to the contemporary challenge, there this clearly a 
growing disconnect between the current structure and focus of the ARQ and what member states 
have recently agreed is important when addressing the ‘world drug problem’.  
Finally, it is also worth mentioning not only the relationship between member states and the data 
they supply to UNODC, but also member state reactions to data drawn from additional sources. In the 
first instance, states are able to challenge particular interpretations and forms of presentation within 
draft versions of the World Drug Report that are perceived to put them in a bad light. However, since 
countries themselves have supplied the data, complaints are generally difficult to sustain. In such 
circumstances anecdotal evidence suggests that irked national officials may be less than cooperative 
in engaging with the ARQ process in future years. Where annoyance is the result of non-member state 
data sources, nations are in a position to challenge them and even force UNODC to rewrite offending 
paragraphs. As occurs at other points within the UN drug control framework, and indeed within the 
wider UN system of which it is a part, the ability to effect change depends greatly upon the geopolitical 
and diplomatic muscle of a particular state. This includes its status within the Commission, which is 
often related to its voluntary financial contributions to the ever cash-strapped UNODC (Bewley-Taylor, 
D and Trace, M, 2006).    
Indicators and the Outcome Document: Limited progress, but some opportunities   
 In the lead up to the 2016 UNGASS, it was possible to identify a growing awareness and related 
discussion within UN fora concerning the increasing inadequacy of the indicators used to assess the 
state of the illicit global drugs market. This assessment was held not only among sections of civil 
society, but also by some member states (Bewley-Taylor, D, 2016). Longitudinal analysis of 
information contained within the World Drug Report, reveals a noticeable and significant shift over 
recent years to include more data on the negative health consequences of drug use (UNODC, 1997). 
This is important, since the UNODC’s flagship publication does much to set the ‘mood music’ for 
discussion in Vienna with member states often referring to its findings during statements within the 
CND plenary as well as during discussions in the Commission’s Committee of the Whole where 
resolutions are negotiated. Moreover, the data generated by the ARQ currently feeds into the 
Executive Director of UNODC’s biennial report to the Commission on action taken by states to 
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implement the 2009 Political Declaration and Plan of Action; document that include a set of 
recommendations for member states (ECOSOC, 2016). 
Nonetheless, at the international level, information collected from states via the ARQ remains 
dominated by a concern for scale and flows; largely process indicators that often tell us more about 
law enforcement activity than the state of the illicit market. It is plausible to suggest that this 
preoccupation is the result of a system traditionally premised on the belief that the most effective 
way to protect the ‘health and welfare’ of humankind, as laid out in the preamble of the bedrock of 
the extant international drug control regime, is to shrink the size of and eventually stamp out the illicit 
market. Such a path dependent approach, however, is at odds with increasingly widespread and more 
nuanced market management-oriented perspectives whereby authorities are focusing on reducing 
the harm associated with not only drug markets themselves, but also those policies designed to 
significantly and measurably reduce the scale of -  and ultimately eliminate -  them.  Consequently, 
and not unreasonably, during preparations for the New York meeting there was some hope, again 
both from some member states and sections of civil society, that the UNGASS would allow for 
substantive discussion of revised policy objectives accompanied by more sophisticated indicators 
pertaining to various forms of drug and drug market-related harm This was particularly so considering 
both the improved understanding of the dynamics of drug markets and their associated harms, and 
the development of innovative metrics taking place within some member states.  
Although often presented as an esoteric and purely technical matter, the political dimension of the 
issue of indicators soon became clear in the intensity of the negotiations of the Outcome Document 
– which was to be agreed by consensus. Moreover, as the discussions unfolded, it grew more obvious 
that many states were willing to side-step what was becoming a contentious issue to secure 
agreement for other aspects of the draft text. Indicative of this was the loss of a proposed – and on 
the face of it relatively innocuous – paragraph in a working draft of the Outcome Document that 
included a call to ‘identify quantifiable indicators…in line with the integrated and balanced 
approach…’.  This was shifted to the so-called ‘car park’, a stand-alone document designated to ‘hold’ 
contested language in order to aid the flow of discussions during negotiations, and failed to gain 
sufficient agreement for inclusion in the final text.    
That said, some positives must be acknowledged regarding the issue of indicators. Involvement within 
the formulation process of a range of UN entities beyond the drug control apparatus in Vienna can 
only be constructive in terms of any future consideration of non-traditional drug policy indicators.1  
Similarly, a move away from the established three-pillar structure laid out in the 2009 Political 
Declaration (‘demand reduction’, ‘supply reduction’ and ‘countering money-laundering and 
promoting judicial cooperation to enhance international cooperation’) also offers opportunities for 
more sophisticated and disaggregated measurement processes, particularly in relation to access to 
controlled medicines,2 a point to which we will return.      
In terms of specific metrics, the Document also includes mention of the target to end the HIV epidemic 
by 2030 ‘among people who use drugs’. This was the compromise language after agreement could not 
be reached to recognize that the 2015 target agreed by the international community to reduce HIV 
transmission by 50 per cent among people who inject drugs had been missed. Furthermore, that the 
Outcome Document explicitly welcomes the Sustainable Development Goals (SDGs) as 
‘complementary and mutually reinforcing’ to drug control, and recommends ‘the use of relevant 
human development indicators’ provides a valuable toe hold for the future development of metrics 
that not only move beyond law enforcement process indicators, but also enhance system-wide 
coherence on the issue. To be sure, linking new and carefully designed indicators to broader UN 
objectives, principles and contemporary UN endeavours, such as Sustainable Development Agenda 
agreed in late 2015, has the potential to bring international drug control policy more into line with the 
UN Charter and other instruments, including those concerning indigenous rights – and to better reflect 
the high-level priorities of the United Nations: achieving human rights, peace & security and 
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development. Any serious discussion of the measurement of drug policy impacts within the broadly 
defined development domain must read across relevant SDGs indicators (Bewley-Taylor, D.R., 2017). 
Beyond these high-level statements of intent, the Document also mentions, at a more granular level, 
areas where member states agree to improve data collection. This includes issues that span both the 
health and organized criminal dimensions of illicit drug markets, and particularly – even though the 
Questionnaire is not mentioned specifically – areas not covered within the current structure of the 
ARQ.3 Furthermore, as discussed below, although problematic in terms of the extant mechanisms, the 
2016 text includes some intriguing possibilities in terms of voluntary reporting.  
Discussion of metrics since the UNGASS: Increasing attention on ARQ revision 
As regular observers of the CND will know, in the past few years the issue of drug policy metrics and 
indicators has become more prominent (IDPC, 2016). The Commission’s 2017 session was no 
exception. No doubt a combination of the Outcome Document, the, in many ways resultant, increasing 
prominence of the SDA within drug policy deliberations and the scheduled high-level review in 2019 
of the targets set in 2009 contributed to this.  
Many states continued to follow the age-old practice of including within statements long lists of 
figures concerning drug seizures and in some cases, such as India, crop eradication. Although countries 
including Tanzania, Algeria and Sudan were part of this group, it was those from the Middle East that 
were particularly noteworthy.   
That said, a significant number of other states noted the inadequacies of traditional metrics. For 
example, the Ambassador to Vienna from Panama highlighted the need for a better framework of 
indicators beyond those relating to seizures, the UK delegate flagged up the importance of improving 
impact indicators concerning actions targeting organised crime and the Netherlands stressed the 
necessity of new indicators and the need to improve statistics and maintain continuous monitoring of 
drug markets. A statement from the Norwegian delegate summed up the situation well and 
highlighted the pressing need to re-visit the data collection mechanisms mandated by member states 
and operated by the UNODC: 
The process up to and the finalizing of the UNGASS revealed a need to collect better and 
more reliable data, and towards viewing international drug policy in a more holistic 
manner.  The metrics designed to measure the effectiveness of interventions would profit 
from more dynamic and sophisticated approaches towards metrics that measure 
outcomes related to individuals and communities in terms of human rights and 
development.  It now seems timely to review the ARQ such that the UN drug control 
apparatus is able to capture data relevant to the commitments made in New York, 
including those relating to the SDGs…The imperative for such a review is also heightened 
by the approach of 2019 and the expiration of the targets set by the 2009 Political 
declaration (Bewley-Taylor, and IDPC, 2017).  
Such reference to a review of the ARQ echoed that made by the Swiss delegation at the CND 
intersessional in September 2016.  Then, among a range of other issues concerning the Questionnaire 
and the SDA, Mr Martin Matter (then Counsellor, Permanent Mission of Switzerland to the United 
Nations in Vienna), raised an interesting point about states furnishing ‘additional information to the 
CND’ than that currently requested by the ARQ, particularly in relation to ‘criminal justice policies and 
practices’ and the ‘promotion of human rights’.  Indeed, Matter’s statement highlighted how the 
current structure of the Questionnaire made the collection of such information difficult (UNODC, 
2016).  This is of particular relevance in relation to Paragraph 4 (h) of the Outcome Document. Under 
‘Operational recommendations on cross-cutting issues: drugs and human rights, youth, children, 
women and communities,’ this notes that member states:  
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Consider, on a voluntary basis, when furnishing information to the Commission on 
Narcotic Drugs pursuant to the three international drug control conventions and 
relevant Commission resolutions, the inclusion of information concerning, inter alia, the 
promotion of human rights and the health, safety and welfare of all individuals, 
communities and society in the context of their domestic implementation of these 
conventions, including recent developments, best practices and challenges (emphasis 
added).  
Another statement worthy of note came from the Mexican delegate who, bringing together several 
themes that emerged during the March meeting, stated that the ‘prohibition approach is never going 
to be enough’ with a better way forward involving the measurement of policy impact on individuals’ 
lives as part of a move to ‘intersectoral multidimensional strategies’.  Building upon positions that had 
been developing over the course of recent CND sessions, new indicators should, the Mexican delegate 
claimed, link closely to the work of a range of UN agencies and are essential to achieving progress 
towards the objectives of the UNGASS Outcome Document.  
Interest within Mexico for the metrics issue was also evident in discussions concerning the work of 
the UN’s New York based Statistical Commission (StatComm). Demonstrating a welcome convergence 
of endeavour across the UN, StatComm presented at its 48th session – the week before the CND – the 
Report of the National Institute of Statistics and Geography of Mexico (INEGI) and the United Nations 
Office on Drugs and Crime on an international road map to improve drug statistics (ECOSOC, 2017). 
Although agreed on for publication some time ago, the report was in many ways a response to the 
Outcome Document. Discussed at various points during the Commission’s 60th session, including 
within the plenary and side events, it was generally well-received (IDPC, 2017). Without offering a full 
critique of the document here, it is fair to say that the international ‘Roadmap’ certainly adds value to 
the current discussions, especially in terms of inclusion within the drafting process of other agencies 
from within and outside the UN (for example the World Customs Organization, CICAD, EMCDDA, and 
WHO).  Involvement of these bodies can provide different perspectives and expertise and have the 
potential to ‘increase synergies’ and ‘coordination’ in data collection. Nevertheless, the Roadmap 
arguably remains overly focused on measuring the scale and flow of drug markets rather than 
multidimensional harms that result from them, or from misguided repressive drug policies.  
All that said, and in terms of the immediate future of the ARQ, probably the key outcome of the March 
2017 session of the CND came in the form of resolution 60/1, Preparations for the sixty-second session 
of the Commission on Narcotic Drugs in 2019 (UN, 2017). Within this the UNODC was invited, in close 
cooperation with Member States,  to ‘reflect on possibilities to strengthen and streamline its existing 
data-collection and analysis tools, including improving the quality and effectiveness of the annual 
report questionnaire, and to report to the Commission on possible ways to enhance these, for 
consideration by the Commission at its sixty-second session’ (UNODC, 2017). Having initiated the 
review process in March, members of the CND also discussed it at the Commission’s intersessional 
meeting in November and the reconvened session the following month. Reiterating the sentiment 
expressed in March, the Norwegian delegate at the intersessional meeting noted how ‘…the UNGASS 
outcome document is a turning point to tackling the world drug problem. It is now time for action, 
implementation and monitoring.’ He then went on to say that, ‘We need new metrics and indicators 
to assess progress. It is timely to review the ARQ so that we can capture data relevant to the 
commitments agreed in New York’ and in relation to the ‘SDGs’ (IDPC, 2017).’ 
Within the context of discussions in Vienna, and agreement in Autumn 2017 around the establishment 
of an ‘Expert group Meeting’ to meet in January 2018, the UNODC began to organize an ‘Expert 
Consultation’ by way of ‘a first step to reflect on ways to improve the current data collection on drugs, 
including the ARQ, and to discuss activities to support countries in the production of drug relevant 
statistics, as for example indicated by the Roadmap (VNGOC, 2017).’ Reflecting on both how to 
‘strengthen and streamline’ UNODC-mandated drug data collection tools and on issues around 
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capacity building, the principal outcome of the consultation is intended to be a report submitted to 
the CND as a ‘room document’ to inform discussions in March 2018 ‘on the possible avenues to 
undertake to improve the quality and availability of drug statistics. (VNGOC, 2017)’ The same 
document will be presented to the 49th session of the UN Statistical Commission, also to be held in 
March 2018 – and a final product will be shared at the 62nd CND in March 2019. 
Reviewing the ARQ: An opportunity to increase synergies with the Outcome Document 
At the time of writing this chapter, December 2017, the precise nature of the work and focus of the 
‘Expert Consultation’ remains fluid. Nonetheless, through the UNODC’s welcome engagement with 
civil society organisations (CSOs), it is becoming clearer how the process is unfolding and where there 
may be opportunities for states, CSOs and UN agencies based outside Vienna to feed into the revision 
of the ARQ and bring it more into line with the aspirations of the UNGASS Outcome Document, its 
calls for an improvement in data capture and movement towards a more rights based approach to 
drug control more generally. The final section of this chapter consequently briefly explores some of 
the key issues arising from the discussions, giving particular attention to issues that appear to have 
been omitted.  
In December 2017, the UNODC launched an online questionnaire to collect feedback on the ARQ from 
governments, UN agencies and civil society organisations. The strategy behind this initiative was that 
responses to the online questionnaire would then result in a report that would be presented as a 
background document for the January 2018 meeting. In relation to possible new topics for data 
collection, the Office’s questionnaire selected only seven issues – apparently based on the Statcomm 
Roadmap: (1) Trends in the composition, production, prevalence and distribution of New Psychoactive 
Substances; (2) Social, economic and other risk factors encouraging drug use; (3) Prevention and 
countering of drug-related crime and drug supply reduction measures; (4) Links between drug 
trafficking, corruption and other forms of organized crime; (5) Money-laundering and illicit financial 
flows; (6) Drug-related criminal activities using the Internet; (7) Factors contributing to illicit crop 
cultivation. These are all relevant issues of interest for the ARQ.  Nonetheless, such an approach leaves 
out several other critical thematic areas for the Questionnaire review process – some directly 
mandated, others suggested, by the UNGASS Outcome Document.  
Human Rights 
As noted above, the Outcome Document explicitly calls on member states to ‘Consider, on a voluntary 
basis…the inclusion of information’ on a range of issues, including human rights (paragraph 4.h). The 
Document also promotes more proportionate penalties for drug offences (paragraph 4.l), and 
alternatives to incarceration (paragraph 4.j). Whether or not member states offer treatment as an 
alternative to incarceration is already included in the ARQ (Part ii, question 9.e).  Nonetheless, these 
two critical issues could be better incorporated within Parts i and ii of the Questionnaire.  
The Outcome Document also calls on member states to ‘Promote and implement effective criminal 
justice responses to drug-related crimes to bring perpetrators to justice that ensure legal guarantees 
and due process safeguards’ and ‘practical measures to uphold the prohibition of arbitrary arrest and 
detention and…torture and other cruel, inhuman or degrading treatment or punishment and to 
eliminate impunity’ (paragraph 4.o).  Mindful of the high-level commitments made to human rights 
values within the Document and other texts, it seems important that the updated ARQ reflects these 
commitments.  This might be achieved either as a new ‘Human rights’ section within the ARQ, or by 
embedding human rights considerations across the various ARQ sections. Additional data (including 
from CSOs) would most probably need to be considered by UNODC for issues where self-reporting by 
UN member states to the Office may present some difficulties (e.g. impunity, acts of torture and ill-
treatment, etc.) – an issue that will need to be addressed in the Expert Group’s deliberations. Other 
UN agencies, notably the Office of the High Commissioner on Human Rights (OHCHR), have done 
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significant work on developing human rights indicators, and such expertise and experience could be 
utilized (OHCHR, 2012). For instance, the OHCHR might consider drafting regular reports on the impact 
of drug policies on human rights as a useful tool to feed into the UNODC World Drug Reports.  
Gender 
 
The Outcome Document provides a clear mandate for the UNODC to collect gender-disaggregated 
data across the spectrum of drug policy, stating ‘that targeted interventions that are based on the 
collection and analysis of data, including age- and gender-related data, can be particularly effective in 
meeting the specific needs of drug-affected populations and communities’ (preamble, emphasis 
added). The Document also promotes non-discriminatory access to health and social services, the 
need to address the protective and risk factors that make women vulnerable to participation in the 
illicit drug market, and the specific needs and vulnerabilities of women drug offenders when 
imprisoned. Currently, the ARQ only requests gender-specific information for alternative 
development and for the overall prevalence of drug use (but not for other critical issues such as drug 
injection, related harms and access to services, or indeed on any issue related to supply-side 
activities).  Although, as a reading of recent World Drug Reports reveals, the Office has been devoting 
increasing attention to the issue of gender, the review might consider the inclusion of requests for 
gender and age-disaggregated data throughout the ARQ. Moreover, it might ask, on a voluntary basis, 
that member states submit information disaggregated by socio-economic status, race, ethnicity and 
other categories as appropriate.  
Additional UNGASS-related data collection 
Several new drug-related issues covered in the Outcome Document could also be considered for 
inclusion within any revised version of the Questionnaire. This might be done both via voluntary 
reporting by member states to the UNODC (possibly by expanding the ‘Additional Comments’ sections 
of the ARQ), or by using the data already being collected by other UN agencies. 
For instance, the ARQ currently requests data on HIV, hepatitis and tuberculosis – as well as on 
interventions like needle and syringe programmes, opioid substitution therapy and others. 
Meanwhile, the Outcome Document expands these health issues to include overdose prevention and 
naloxone distribution (paragraph 1.m). The Expert group might consequently consider requesting 
member states to report, on a voluntary basis, on progress made towards preventing overdose deaths. 
Further developing the inter-agency cooperation involved in Statcomm’s production of the Roadmap, 
data collected by other UN agencies on this issue, especially by the WHO, could be included.   
Crucially, the Outcome Document dedicates an entire chapter to ensuring adequate availability of 
controlled substances for medical and scientific purposes.  This is one of the key objectives of the UN 
drug control treaties and an issue that has been growing in prominence in recent years as research 
reveals disparities in access to essential medicines in many parts of the world (Global Commission on 
Drug Policy, 2015).  While this is the case, the current ARQ does not address this issue. Better data is 
essential both for informing policy action by states to improve access to controlled medicines, to take 
corrective action when problems with their use occur, and for measuring progress over time. The 
International Narcotics Control Board (INCB), the ‘independent and quasi-judicial monitoring body for 
the implementation’ of the drug control conventions (INCB, ?), routinely collects information on the 
consumption of controlled medicines.  It therefore seems reasonable for the Expert Group to consider 
the use of this valuable data the future analysis of the world drug situation. In addition, the Group 
might call upon UNODC to request that, on a voluntary basis, member states report back on progress 
made towards other relevant questions identified in the Document, in particular removing legislative 
and technical barriers to accessing controlled medicines, and improving training for healthcare 
providers.  
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Reviewing the scope of the new thematic areas  
As noted above, it appears as if only seven possible new topics for data collection have been identified 
by the Statcomm and UNODC. Among these is ‘Social, economic, and other risk factors encouraging 
drug use’. Available data from the Office itself shows that there are no common trends on drug use or 
the risk factors associated with it – drug use happens across all ages, genders, cultures and political 
systems. That said, problematic use, drug dependence and drug-related health harms (e.g. HIV and 
hepatitis C infections, tuberculosis and overdoses) are often concentrated in marginalised, 
impoverished, conflict-afflicted areas across the globe. Consequently, it may be more relevant for the 
Expert Group to consider the social, economic and other risk factors around problematic drug use and 
harms, including poverty, social inclusion, criminalisation, policing, incarceration, gender inequality, 
armed conflicts, and so on.  
In addition, it will be recalled that the seventh thematic area listed by the UNODC relates to the 
‘Factors contributing to illicit crop cultivation’. While these factors are critical, the Outcome Document 
also commits member states to address ‘drug-related socioeconomic issues’ related to all supply-side 
drug control – cultivation, manufacture, production and trafficking – through development-oriented 
drug policies (paragraph 7). This appears to be an opportunity for the ARQ to cover broader 
development concerns in involvement in all illicit drug supply activities – hence contributing to 
member states’ reporting requirements within the 2030 Agenda for Sustainable Development. 
Furthermore, and as mentioned above, paragraph 7.g of the Document promotes the ‘use of relevant 
human development indicators’ – another dataset that could be utilized to support the UNODC’s 
analysis of drug policy issues globally.  
Conclusion 
Any revision of the ARQ is clearly a complex process; one that involves not only myriad technical 
challenges but also, and as is likely to become more obvious in the months before March 2019, deeply 
ingrained political and systemic tensions. While arguably limited in scope, the seven possible new 
topics for data collection are all fraught with conceptual and methodological dilemmas. As briefly 
discussed here, both ‘Social, economic, and other risk factors encouraging drug use’ and ‘Factors 
contributing to illicit crop cultivation’ are fiendishly intricate and require a holistic perspective, 
including the promotion of linkages to the SDGs.  Moreover, although not unique within the list, the 
collection of meaningful data around new forms of drug market such as the darknet and indicators 
around drug-related corruption will be particularly difficult.   
While in some instances, such as crypto-drug markets, a revised ARQ may require the capture of new 
data, in other instances information might be mined from existing data sets; sets that are already 
being generated both within the UN system by agencies other than the UNODC and non-governmental 
organisations (NGOs) (Bewley-Taylor, D, 2016). For example, in addition to utilizing data on essential 
medicines collected by the INCB, any revised process might incorporate data from NGOs working in 
the sector (The Economist, 2015).   
In terms of improved cooperation with non-Vienna based UN agencies, it should be recalled how in 
its Roadmap, the Statistical Commission concluded that ‘international and regional bodies…should 
increase synergies and improve the coordination and their statistical work in the area of drugs, 
including with respect to reporting on the indicators and targets related to the Sustainable 
Development Goals’ (emphasis added) (UNODC, 2016). In parallel with the ARQ review process, it 
seems logical therefore for the UNODC to access relevant drug-related information already being 
collated by other UN agencies and related bodies. This would prevent a significant additional burden 
on member states for data collection, while promoting more system-wide coherence within the UN 
for data collection and analysis within their respective mandates. This could include, inter alia, data 
collected by the WHO,4 UNAIDS,5 UNICEF,6 the INCB,7 the World Bank,8 the OHCHR,9 the Committee 
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on the Prevention of Discriminations Against Women,10 the United Development Programme via the 
Human Development Index,11 and the Sustainable Development Goals.12 Mindful of the UNODC’s 
current use of data sets from a range of bodies to complement that generated by the ARQ, such a 
widening of scope should not be beyond the realms of possibility.   
That said, in additional to substantial technical challenges, several fundamental problems can be 
identified. First, mindful of the increasingly complex and fluid state of the world drug market, it is 
difficult to reconcile the request within resolution 60/1 to simultaneously ‘strengthen’ and 
‘streamline’ the ARQ, particularly if many of the existing categories concerning scale and flows are 
retained. Indeed, although there remains an understandable desire to reduce the burden on member 
states, particularly since the collection of good quality data is so expensive, it appears as if a better 
understanding of the ‘world drug problem’ requires more data, not less.  Second, any shifts away from 
the longstanding interest in flows and scale, as contained within the Outcome Document, raises the 
sticky twin issues of self-reporting and state sovereignty, including when this involves data from non-
state actors.  As has been raised elsewhere and mentioned briefly above, that the entire ARQ process 
is based on self-reporting raises some serious questions.  There is certainly something to be said for 
the view that ‘States naturally have an inbuilt bias against reporting failures or poor performance, a 
problem assumed to be most acute in states or regions of greatest concern’ (Rolles, S. et al, 2016).  
Reporting poor performance within the domain of human rights, however, goes well beyond the issue 
of drug policy and the work of the UNODC and an Expert Group.  It strikes at the heart of the systemic 
tension inherent within the UN system: differing perceptions of the appropriate balance between 
states’ obligations and state sovereignty. To be sure, while the language of human rights now 
permeates soft law instruments (such as the Outcome Document) within the realm of drug policy, 
there clearly remains substantial differences of view within the international community.  These are 
differences that, while often side-stepped within Vienna, New York, and to a lesser extent Geneva, 
can be seen to play out within the domestic sphere. As touched upon here, the option of voluntary 
reporting may be the most realistic first step in capturing states’ performance on drug policy vis-à-vis 
human rights obligations. That some states may choose not to offer information may speak volumes 
in terms of the creation of new normative standards. Another, or possibly additional, route may be 
the use of proxy human rights indicators such as incarceration rates for drug-related offences. 
Ultimately, however, it may be the case that adequate human rights indicators will not fit within 
anything other than a fundamentally redesigned and reframed ARQ; an unlikely prospect bearing in 
mind the apparent systemic inertia within Vienna. In such circumstances, recourse to other 
measurement and review mechanisms, including the SDGs and those in Geneva relating to the work 
of the OHCHR such as the Annual Report, the Universal Periodic Review and Special Procedures 
mechanisms, may be more realistic options.  In whichever part of the UN system the monitoring of 
human rights outcomes of drug policy takes place, it seems clear that the establishment of a 
monitoring framework is essential for the operation of a modern and internally coherent international 
drug control system. Indeed, as Rodrigo Uprimny and Diana Esther Guzman point out, appropriate 
‘indicators to evaluate drug policies are fundamental’ for a human rights approach to the issue area.  
‘Although current indicators are important to measure some aspects of efficacy of drug policies’, they 
continue, ‘supplementary indicators are needed to assure’ the fulfilment of ‘human rights obligations’ 
(Uprimny, R. and Guzman, D.E., unpublished). 
Indeed, whatever the route forward, it is becoming increasingly clear that for the language within the 
Outcome Document to be meaningful there must be an appropriate set of performance indicators 
and associated capture mechanisms.  On this point it is worth recalling the words of Bente Angell-
Hansen, Norway’s Ambassador to Austria and Head of the Norwegian Mission to the United Nations, 
Vienna.  Speaking at a side-event at the reconvened session of the CND in December 2017, she evoked 
the maxim, ‘If you have a problem that you don’t want to do anything about – don’t measure it (IDPC, 
2017).’ How states choose to measure or avoid measuring various facets of the world drug problem, 
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the human rights issue prominent among them, looks set to be a key area of concern in the lead up 
to 2019 and beyond.      
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